Home NDC 0026-3944-25 Jivi
Product NDC 0026-3944
Requested package NDC 0026-3944-25
11-digit product format 000263944
Labeler code 0026
Product ID 0026-3944_15230046-a8a7-4a1c-b279-ae307d278515
Type PLASMA DERIVATIVE
Nonproprietary name Antihemophilic Factor (Recombinant) Pegylated-aucl
Dosage form KIT
Labeler Bayer HealthCare LLC
Application BLA125661
Marketing category BLA
Marketing start 2018-08-30
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base Jivi
Listing expiration 2027-12-31
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2055659 Internal RxNorm lookup 2055664 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# NDC, Effective, Related label table NDC Effective Related label 0026-3944-25 2021-09-07 These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018 0026-3944-99 2021-09-07 These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018 0026-3944-25 2021-01-29 These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018 0026-3944-99 2021-01-29 These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0026-3944-25 Jivi 1 in 1 BOX KIT 1 13 0026-3944-99 Jivi 1 in 1 BOX KIT 1 13 0026-4944-01 Jivi 2.5 mL in 1 VIAL, SINGLE-USE INJECTION, POWDER, LYOPHILIZED, 2.5 mL 1000 [iU] in 2.5mL 13 0026-4944-99 Jivi 2.5 mL in 1 VIAL INJECTION, POWDER, LYOPHILIZED, 2.5 mL 1000 [iU] in 2.5mL 13
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0026-3944 JIVI (ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED-AUCL) KIT [BAYER HEALTHCARE LLC] 11 Current NDC, Legacy NDC, 4 package rows 20250529_f04e5bd5-d7e2-453b-a407-2616d81a695d.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 125661 Jivi Antihemophilic factor (recombinant), PEGylated-aucl 351(a) Rx 2026-10-01
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 0026-3944-25 00026394425 1 KIT in 1 BOX (0026-3944-25) * 2.5 mL in 1 VIAL (0026-4944-99) * 2.5 mL in 1 SYRINGE (0026-0426-02) * 2.5 mL in 1 VIAL, SINGLE-USE (0026-4944-01) 1 kit 2018-08-30 0000-00-00 No No Current